Auxilium Pharma (AUXL $18.88 +0.14) reported second quarter earnings
of ($0.11) per share, $0.08 better than the Capital IQ Consensus Estimate of
($0.19).
Revenues rose 30.5% year/year to $65.9 million versus the $64.5 million
consensus.
The company is decreasing full year 2011 guidance for XIAFLEX U.S. revenues from
the previously stated guidance of a range of $50 to $60 million to a range of
$45 to $50 million.
The decrease in XIAFLEX U.S. revenues guidance changes full year 2011 net loss
guidance from the previously stated guidance of a range of $(31) to $(41)
million to a range of $(40) to $(45) million for the year.
"We believe that the progress we made in the second quarter of 2011 will drive
long term shareholder value. XIAFLEX showed double-digit sequential growth over
the first quarter of 2011 and we remain encouraged by the success stories on
XIAFLEX use, reflecting a steady shift in the treatment paradigm. Testim
continued to perform well, despite several new competitors entering the market,
with prescriptions posting growth over the second quarter of 2010 and over the
first quarter 2011."






